Teixeira, Henrique D
AbbVie (United States)
3 papers on CoChatORCID 0000-0001-5488-3556
Most cited papers
- Verified
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
Guttman-Yassky, E., Teixeira, H. D., Simpson, E. L., Papp, K. A., Pangan, A. L., Blauvelt, A., Thaçi, D., Chu, C.-Y., Hong, H. C.-H., Katoh, N., et al. (2021) · The Lancet
Dermatology and Skin DiseasesAsthma and respiratory diseases
Cited by 583
- Verified
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
Blauvelt, A., Teixeira, H. D., Simpson, E. L., Costanzo, A., De Bruin-Weller, M., Barbarot, S., Prajapati, V. H., Lio, P., Hu, X., Wu, T., et al. (2021) · JAMA Dermatology
Dermatology and Skin DiseasesAsthma and respiratory diseases
Cited by 516
- Verified
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
Reich, K., Teixeira, H. D., de Bruin-Weller, M., Bieber, T., Soong, W., Kabashima, K., Werfel, T., Zeng, J., Huang, X., Hu, X., et al. (2021) · The Lancet
Dermatology and Skin DiseasesAsthma and respiratory diseases
Cited by 402
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free